2020年3月胃食管反流病是胃食管腔因过度接触或暴露于胃液致胃食
管反流症和食管黏膜损伤的疾病[1]，其在国内发病率约占6.7%[2]。
胃食管反流不仅会造成消化系统的损害，而且可累及呼吸系
统，严重影响患者的生活及工作。针对胃食管反流病患者，临
床多采用药物质子泵抑制剂（兰索拉唑片），但单用一种
药物，起效缓慢，不足以控制疾病进展。临床研究表明，曲
美布汀具有调节消化道运动及镇吐作用，在胃食管反流
病上具有良好的临床效果[3]。鉴于此，本研究选择2017年6月至2019年6月我院接收并诊治的80例胃食管反流病患者为研究对象，分别采用兰索拉唑片、曲美布汀联合兰索拉唑片两种用药方案进行，并评价临床效果及对患者食管远端平滑肌运动功能的影响，现报道如下。1资料与方法1.1一般资料选择2017年6月至2019年6月我院接收并诊治的80例曲美布汀联合兰索拉唑片胃食管反流病的
trime
临床效果
徐兴会1，高红霞2*
（1.延安市洛川县中医医院，陕西延安，727400；2.延安市博爱医院，陕西延安，716000）
摘要：目的探讨曲美布汀联合兰索拉唑片胃食管反流病的临床效果。方法选择2017年6月至2019年6月我院接收并诊治的80例胃食管反流病患者为研究对象，按随机数字法将其分为质子泵抑制剂组和联合组，每组40例。质子泵抑制剂组采用兰索拉唑片，联合组采用马来酸曲美布汀片联合兰索拉唑片。比较两组患者的效果。结果前，两组患者的GerdQ 、GERD-HRQL 各项评分比较，差异无统计学意义（P 跃0.05）；8周后，两组患者的GerdQ 、GERD-HRQL 各项评分均明显降低，且联合组低于质子泵抑制剂组，差异具有统计学意义（P <0.05）。前，两组患者的LESP 、蠕动性收缩比例、LESRR 及DCI 比较，差异无统计学意义（P 跃0.05）；8周后，两组患者的LESP 、蠕动性收缩比例、LESRR 及DCI 均明显升高，且联合组高于质子泵抑制剂组，差异具有统计学意义（P <0.05）。8周后，联合组的总有效率明显高于质子泵抑制剂组，差异具有统计学意义（P <0.05）。结论曲美布汀联合兰索拉唑片胃食管反流病的临床效果显著，值得临床推广应用。
关键词：胃食管反流病；曲美布汀；质子泵抑制剂；兰索拉唑
中图分类号：R571文献标志码：A 文章编号：2096-1413(2020)07-0051-03
DOI:10.19347/jki.2096-1413.202007021作者简介：徐兴会（1976-），女，汉族，陕西延安人，主治医师。研究方向：胃食管反流病。*通讯作者：高红霞，E -mail :525378178@qq.
Clinical effect of trimebutin combined with lansoprazole tablets in the treatment of gastroesophageal reflux disease
XU Xing-hui 1,GAO Hong-xia 2*
(1.Luochuan Hospital of Traditional Chinese Medicine,Yan'an 727400;2.Yan'an Bo'ai Hospital,Yan'an 716000,China)ABSTRACT:Objective To investigate the clinical effect of trimebutin combined with lansoprazole tablets in the treatment of gastroesophageal reflux disease.Methods Eighty patients with gastroesophageal reflux disease admitted and treated in our hospital from June 2017to June 2019were selected as the study objects.The patients were divided into proton pump inhibitor group and combined treatment group according to the random number method,with 40patients in each group.The proton pump inhibitor group was treated with lansoprazole tablets,and the combined treatment group was treated with trimebutin combined with lansoprazole tablets.The therapeutic effects of the two groups were compared.Results Before treatment,there were no significant differences in the scores of GerdQ and GERD-HRQL between the two groups (P >0.05);after 8weeks
of treatment,the scores of GerdQ and GERD-HRQL in both groups decreased significantly,and those in the combined treatment group were lower than the proton pump inhibitor group,the differences were statistically significant (P <0.05).Before treatment,there were no significant differences in LESP,peristaltic contraction ratio,LESRR and DCI between the two groups (P >0.05);after 8weeks of treatment,LESP,peristaltic contraction ratio,LESRR and DCI in both groups increased significantly,and those in the combined treatment group were higher than the proton pump inhibitor group,the differences were statistically significant (P <0.05).After 8weeks of treatment,the total effective rate of treatment in the combined treatment group was significantly higher than that of the proton pump inhibitor group,and the difference was statistically significant (P <0.05).Conclusion Trimebutin combined with lansoprazole tablets in the treatment of gastroesophageal reflux disease has a significant clinical effect,which is worthy of clinical promotion and application.KEYWORDS:gastroesophageal reflux disease;trimebutine;proton pump inhibitor;lansoprazole
临床医学
51--

版权声明：本站内容均来自互联网，仅供演示用，请勿用于商业和其他非法用途。如果侵犯了您的权益请与我们联系QQ:729038198，我们将在24小时内删除。